Abstract
Soluble oligomers of the Abeta peptide (AbetaOs) are the major neurotoxins related to cognitive deficits in Alzheimer's disease (AD). With increasing life expectancy of the population, and absence of efficient pre-mortem diagnostic and treatment methods for AD, conformational antibodies specific for AbetaOs are seen as a promising therapeutic strategy. However, clinical trials with anti-A…